The biotech sector resembles a minefield these days, but a pair of companies have lots of cash on their books are well fortified to weather the onslaught.
By Bob Ciura | Jan 8, 2016
After a whipsaw year for Big Pharma stocks in 2015, there are some compelling value opportunities out there.
By Jay Taylor | Apr 14, 2015
Biotechnology stocks are leaving the Nasdaq Composite in the dust. Is it sustainable? Or are we looking at a biotech bubble?
By Marshall Hargrave | Feb 11, 2015
Pinpointing the market's next big move is nearly impossible, but for investors with a longer-term horizon, it looks like biotechs are still early on in a multi-year bull run.